The Prostate Cancer Foundation (PCF) funds the world's most promising research on the biology and treatment of prostate cancer, accelerating those discoveries into therapies and strategies designed to improve the quality of life and overall survival of patients.

The Prostate Cancer Free Foundation, formerly the Prostate Cancer Treatment Research Foundation, was established in November of 2010 as a NON-PROFIT 501-C. The Foundation works to help people interested in and affected by prostate cancer through education and research.

The Prostate Cancer Treatment Center Foundation prostatecancerfree.org was established in November 2010 to help prostate cancer patients by improving treatments through education and research.

FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers. PARP inhibitors like talazoparib block PARP proteins from repairing damaged DNA, leading to further DNA damage and cell death.

A new treatment for advanced prostate cancer improves survival in phase 3 clinical trial. Radiation therapy is getting more precise, enabled by technologies that make it easier to kill tumors while sparing their surrounding tissues.

Supplements cannot cure or treat prostate-related issues. However, many claim to help prevent or lessen the symptoms associated with prostate problems, generally by reducing inflammation. The prostate gland wraps around the urethra and helps produce fluid in semen.

Your diet should be:

• Primarily plant-based.
• Include plenty of fruits and vegetables.
• High in fiber.
• Low in fat.
• Limited in the amount of simple sugars.

In general, the earlier prostate cancer is caught, the more likely it is for a man to get successful treatment and remain disease-free. The overall prognosis for prostate cancer is among the best of all cancers.

The approval, announced on June 20, makes talazoparib the third PARP-blocking drug to be cleared by the agency to treat prostate cancer. FDA based the approval on a set of data from a large, randomized phase 3 clinical trial called TALAPRO-2 - funded by Pfizer, the maker of talazoparib.

Results from the still-unpublished study were presented at the 2023 American Society of Oncology Annual Meeting in June. After a median follow-up of roughly 17 months, the enzalutamide/talazoparib combination reduced the risk of death or visible signs of tumor progression by 55%.

Enzalutamide works by blocking hormones from fueling cancer cell growth. The approval, announced on June 20, makes talazoparib the third PARP-blocking drug to be cleared by the agency to treat prostate cancer.

Novel Drug-Immunotherapy Combo Boosts Survival in Rare Prostate Cancer. Adding BXCL701 to Keytruda tended to improve overall survival outcomes for patients with small cell neuroendocrine prostate cancer, according to phase 2 study results.